Alcohol-associated liver disease is associated with less adverse outcomes compared to nonalcohol-associated liver disease in patients with COVID-19.

ABSTRACT:

Background

A multicenter cohort of patients hospitalized with COVID-19 was examined to consider the impact of comorbid liver disease in general, and alcohol-associated liver disease (ALD) in particular, on short-term outcomes.

Methods

Data from patients with COVID-19 hospitalized at 21 participating healthcare systems between February 2020 and January 2022 were examined. The analyses used generalized linear mixed model logistic regression including random intercepts to account for clustering within healthcare systems.

Results

Among 145,944 patients hospitalized with COVID-19, 7951 (5.4%) had comorbid liver disease; 1153 (14.5%) had ALD, and 6798 (85.5%) had nonalcohol-associated liver disease (NAALD). The presence of liver disease was associated with increased mortali

SUBMITTER: Musto JA 

PROVIDER: S-EPMC12463747 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature